Articles tagged with T Cell Responses
Researchers found that CD4+ T lymphocytes — immune system cells — produced by people who received COVID-19 vaccines persisted at high levels six months after vaccination, with a significant response against the delta variant. The study also showed that vaccine-elicited fighters recognize and help attack coronavirus delta variant.
Researchers discovered inhibiting or genetically deleting the MTHFD2 enzyme reduced disease severity in various inflammatory disease models. This suggests that MTHFD2 function is important for immune cell regulation, particularly for T cell subsets involved in inflammation.
Researchers have discovered a new target for COVID-19 vaccines that could complement existing vaccines by inducing an immune response against 'replication proteins', essential for the viral cycle. The approach may lead to the creation of a pan-coronaviruses vaccine protecting against SARS-CoV-2 and other coronaviruses.
Researchers found that activated neutrophils release proteins like galectin-9, triggering chronic inflammation and oxidative stress. Early screening for HIV is crucial, and finding ways to reduce negative effects of the infection could be key to improving outcomes.
Researchers are developing a transformative technology called Multiscale Intelligent Convergence (MusIC) to map the complexity of T cells and identify attributes essential for patient benefit. The goal is to create more reliable biomanufacturing of T cell infusion products and engineering potent immune cells.
Researchers found that certain T cells stop working before entering the tumor due to changes in gene expression, making ICB therapies less effective. Combining ICB with other forms of immunotherapy targeting different aspects of T cell function may improve response rates for non-small cell lung cancer patients.
A mathematical model has been developed to better understand the immune response to vaccines, which could improve vaccine design and simplify technical challenges. The model shows that antibodies and cytotoxic T cells cooperate multiplicatively, providing vaccine developers with options for their design.
Researchers discovered that a lower dose of the first shot, followed by a full-dose booster, significantly improved SARS-CoV-2 vaccine potency in mice. This approach, which involves an extended prime-boost interval, may lead to more robust and durable immune responses.
Patients with multiple myeloma often mount a poor antibody response to COVID-19 vaccines and have a weak T cell response, underscoring the need for booster vaccination and safety precautions. Researchers found that these patients are at high risk of severe COVID-19 infection.
Researchers found that both Pfizer and Moderna vaccines generate long-term populations of T cells that can recognize multiple variants of the SARS-CoV-2 virus. However, individuals with a prior COVID-19 infection showed improved T cell responses in the respiratory tract, suggesting better protection against breakthrough infections.
Researchers at UC San Diego School of Medicine report that children with multisystem inflammatory syndrome in children (MIS-C) have normal T cell responses to the COVID-19 virus, contrary to previous hypotheses. This suggests that MIS-C may not be caused by an abnormal immune response to the virus.
Researchers found that T-cell tests are prone to false-positive responses due to cross-reactive reactions with other infections. The study suggests that these tests should not be used for individual diagnosis, but may still have a role in research and studies.
Researchers comprehensively review T-cell responses to respiratory viral infections and chronic obstructive pulmonary disease (COPD), highlighting key characteristics of peptide-reactive T-cells. The review aims to improve understanding of the underlying mechanisms, leading to more effective immune protection and treatment methods.
Researchers found that patients with MS receiving aCD20 treatment generated robust CD4 and CD8 T cell responses to the COVID-19 vaccination. The study measured both antibody and T cell responses in 20 patients with MS who were undergoing aCD20 treatment, compared to those in a group of healthy controls.
MIT researchers have found that vaccinating against certain cancer proteins can boost the overall T cell response and help to shrink tumors in mice. The study identifies specific neoantigens that, when targeted with a vaccine, can reawaken dormant T cell populations and lead to tumor regression.
A new study from La Jolla Institute for Immunology shows that the Moderna COVID-19 vaccine generates durable T cell memory and antibodies, even in people over 70. The researchers found strong CD4+ and CD8+ T cell responses to the vaccine, comparable to those seen in recovered COVID-19 patients.
A study found that the ability to lose control over HIV is linked to a decrease in proliferative and cytolytic ability of immune cells, years before actual virus loss. In contrast to other infections, T cell dysfunction here impairs their response only to HIV.
Scientists at UCL and Francis Crick Institute developed a novel tool that rapidly estimates the number of T cells in cancerous tumors, helping predict patient response to immunotherapy. This method uses DNA sequencing data from patients' cancerous tumours to quantify T cell abundance.
Researchers have discovered a simple and rapid method to measure the T-cell immune response to SARS-CoV-2, which causes COVID-19. The Cytokine Release Assay (CRA) test can reliably identify and quantify specific T cells in vaccinated individuals or those who have recovered from the disease.
A new study found that immune checkpoint inhibitors are effective against HPV-positive head and neck cancers, with a potential therapeutic vaccination approach also being explored. Researchers discovered tumor-specific CD8 T cells in tumors from patients, which could provide a proliferative burst in response to PD-1 blockade.
A new approach has identified T cells in Covid-19 patients, revealing their appearance, number, and activity level against SARS-CoV-2. The study distinguishes between active and dormant T cells, enabling a better understanding of the immune response to the virus.
The study found that the first dose of mRNA vaccine primes the immune system, while the second dose boosts the T-cell response, which can last for years. In people with a history of COVID-19, the T-cell response was already robust after the first dose, with no significant increase after the second dose.
Researchers at the University of Pennsylvania School of Medicine have identified a new mechanism of resistance in advanced chronic lymphocytic leukemia (CLL) patients to CAR T cell therapy. They found that inhibiting the BET protein with the small molecule inhibitor JQ1 can reinvigorate exhausted T cells and increase their production.
Scientists investigated a method to enhance immunotherapy for lung cancer and found that combining it with certain chemotherapy drugs could eliminate harmful immune cells. This approach showed promising results in preclinical studies, inducing the regression of about 70% of tumors.
Researchers developed a protein-based COVID-19 vaccine that mimics the SARS-CoV-2 virus shape, eliciting both antibody and T cell responses. The vaccine, using polymersomes decorated with multiple copies of the receptor binding domain antigen, shows promise for longer-lasting immunity.
New research in monkeys reveals T cell depletion does not induce severe disease. Despite this, strongly depleted macaques still develop potent memory responses to a second infection. The study's findings suggest antibody responses are more critical for protection by vaccination.
Researchers have found that T cells, a key part of the immune system, remain exhausted even after exposure to a virus ended. This limitation affects immune-based therapy research and may require new approaches to treat chronic viral infections and cancers.
A new study found that patients taking immunosuppressants like methotrexate had weaker antibody responses to the Pfizer COVID-19 vaccine after the first dose. However, T-cell responses were preserved in these patients, suggesting potential risks and benefits of vaccinating immunocompromised individuals.
A recent study by HKUST scientists analyzed data from over 850 recovered COVID-19 patients and found that most T cell epitopes targeted upon natural infection are unaffected by current SARS-CoV-2 variants. This suggests that T cell responses may be relatively robust, assuming vaccine responses mimic those of natural infection.
Researchers from La Jolla Institute for Immunology have found that human T cells can target more than 1,400 sites on the SARS-CoV-2 virus, revealing a broad and diverse immune response. This analysis can help monitor effective responses to COVID-19 vaccines and track variations in T cell responses.
A new study found that immunocompromised pediatric patients showed significant T-cell activity and humoral immunity against SARS-CoV-2. The research suggests that vaccination may still be beneficial for this population, particularly those with antibody deficiency disorders. Further studies are needed to confirm these findings.
Vijay Kuchroo's research unravels the immune mechanisms of Multiple Sclerosis, identifying key proteins and molecules that regulate T cell activity. His work opens pathways to develop immune-modulating therapies and advance treatments for MS.
A study found that asymptomatic COVID-19 patients have similar T cell responses to symptomatic patients, but with higher IFN gamma and IL-2 levels. This suggests a key role for T cells in controlling SARS-CoV-2 infection without triggering severe symptoms.
A new study suggests that individuals who remain asymptomatic after SARS-CoV-2 infection have a highly efficient and balanced anti-viral cellular response. This response produces a careful balance of pro- and anti-inflammatory molecules, protecting the host without causing symptoms.
Dendritic cells, key immune responders, can reprogram their genes to enhance immune response by changing epigenetic marks on DNA. This new mechanism could lead to improved vaccination and immunotherapy strategies.
Research highlights the importance of understanding T cell responses in COVID-19, including their role in generating durable immunity and influencing disease severity. Filling knowledge gaps is crucial for developing effective vaccines and treatments.
Researchers found that a majority of HIV-specific T cells can detect and respond to viruses with the capacity to rebound following treatment interruptions. This knowledge could contribute to the development of new treatments against HIV infection. The study suggests that T cells play a crucial role in controlling viral rebound.
Researchers found that a strong, coordinated T cell response is predictive of milder disease, while poor immune coordination leads to severe outcomes. Older adults' susceptibility to COVID-19 may be linked to declining naïve T cells and weaker adaptive immune responses.
Researchers identified a strong and specific T cell response in COVID-19 patients who recovered from mild cases, suggesting a long-lived immunity. The study found that these patients' CD4+ T cells belonged to the Th1 category, which effectively fights viruses and stimulates antibody production.
Researchers found that mild COVID-19 cases can elicit robust memory T cell responses, even in the absence of detectable virus-specific antibody responses. These responses may play a significant role in preventing recurrent episodes of severe disease.
Emerging evidence highlights T cells' role in protecting against viral infections, with antibody responses appearing short-lived and T cell memory potentially more durable. Standardized testing methods for T cell immunity to SARS-CoV-2 are needed to fully understand population-level immunity.
Researchers found SARS-CoV-2-specific CD4+ and CD8+ T cells in COVID-19 patients and 2 uninfected controls, supporting the development of protective virus-specific T cells. The study suggests that these T cells can increase over time, especially for those with severe respiratory symptoms.
Researchers found that coronavirus cases have significantly low T cell counts, negatively correlated with case severity. T cell exhaustion leaves patients more vulnerable to secondary infection. The study suggests targeting treatment for COVID-19 based on T cell counts and function.
Researchers identify CD1a as a key player in triggering T cell responses to allergens in personal care products, shedding light on the 'molecular missing link' behind allergic contact dermatitis. The study highlights the importance of fragrance molecules like farnesol in initiating immune responses.
Researchers at Washington University School of Medicine found that T cells play a critical role in protecting against staph infections. The study suggests activating untapped immune cells and immunizing infants before birth to block toxin effects. This new approach shows promise for developing an effective staph vaccine.
Scientists at La Jolla Institute for Immunology found no evidence linking CD4 T cells to severe dengue hemorrhagic fever. Instead, they discovered a novel T cell response that may help counteract inflammation, suggesting a new direction for developing effective vaccines.
Researchers found that CD8+ T cells retain protective functions despite sustained inhibitory receptor expression during Epstein-Barr virus infection. Blocking the PD-1 pathway leads to specific defects in controlling the virus and increases tumor formation.
A study published in Science Translational Medicine found that early antiretroviral treatment can preserve functional CD8 T cells and stimulate robust CD4 T cell responses. This could lead to the development of effective HIV vaccines by stimulating long-term immune memory.
A phase I clinical trial found that a combination of chemotherapy and HER2-targeted CAR T cells is safe and effective in treating advanced sarcoma, with some patients experiencing complete responses. The therapy showed promising antitumor activity and minimal treatment-related toxicities.
A new pan-filovirus T-cell vaccine has been developed to protect against multiple filovirus species, including Ebola and Marburg. The vaccine induces killer T cells against conserved regions of inner filovirus proteins, offering potential protection against other known and unknown viruses in the filovirus family.
High ambient temperatures reduce food intake, body weight, and immune response in mice infected with viral pathogens like the flu virus and Zika virus. Nutritional supplementation may enhance immune responses to emerging infectious diseases in tropical or developing countries.
A study published in PLOS Pathogens suggests that CD4+ T cells are essential for local control of viral infection and can confer protection against lethal doses of the Zika virus. The findings support the development of vaccines targeting this cell type, which may be safe and effective against infection in multiple contexts.
Researchers observed age-related changes in T cell mitochondrial size and respiratory capacity. Supplementing aged mice with formate and glycine improved T cell survival and growth, suggesting potential therapeutic strategies for boosting immune responses in older individuals.
Researchers have identified a cellular target that may improve vaccine efficacy in immunocompromised individuals, who are highly susceptible to fungal infections. The study found that targeting CBLB, a protein important in regulating immune response, can elicit immunity through a unique T cell pathway.
A new study found that CD4+T cells play a crucial role in protecting against Zika-induced neurological symptoms. Mice lacking these immune cells showed more severe symptoms and increased mortality, highlighting the need for vaccines that elicit robust CD4+T cell responses.
Researchers identified four mechanisms by which Fibroblastic Reticular Cells dampen down T cell responses, including pathways involving prostaglandin E2 and transforming growth factor beta. The study's findings have significant implications for understanding immune responses in situations where T cells don't work as well as they should.
Researchers at La Jolla Institute found that the current whooping cough vaccine primes the immune system in a way that leaves it vulnerable to future infections. The study suggests that new vaccines could be developed to improve the vaccine's efficacy, potentially applicable to other vaccines.
Researchers discover mTORC1 regulates cell growth and metabolism in developing T cells, favoring development of unconventional T cells. Disrupting mTORC1 leads to metabolic changes, altering T cell fate.
Researchers have generated tools to understand the pig immune system's killer T cell responses to influenza, allowing for the design of more effective vaccines. The breakthrough research uses a unique line of pigs and can be applied to other important pig diseases such as foot-and-mouth disease and African swine fever.
A new type of cancer vaccine made from patients' own immune cells has yielded promising results in an initial clinical trial. The vaccine triggers a broad anti-tumor T-cell response, with half of the vaccinated patients showing signs of improved survival and one patient remaining disease-free for five years.